五洲医疗 (301234.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	454.8M	458.3M	477.4M	533.7M	547.1M
Cost of Revenue	385.7M	391.5M	392.5M	420.0M	424.4M
Gross Profit	69.1M	66.8M	85.0M	113.7M	122.7M
Operating Expenses
R&D Expense	9.2M	9.7M	13.0M	13.5M	13.1M
SG&A Expense	—	—	—	—	—
General & Admin Expense	19.1M	19.5M	19.0M	19.9M	30.2M
Selling & Marketing Expense	18.9M	18.2M	14.1M	15.3M	13.1M
Other Expenses	—	—	—	—	—
Total Operating Expenses	53.0M	50.2M	40.4M	43.4M	51.3M
Cost and Expenses	438.7M	441.7M	432.8M	463.3M	475.8M
Operating Income (EBIT)	25.8M	23.5M	46.9M	68.5M	62.1M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	25.4M	22.9M	46.5M	70.9M	73.4M
Income Tax Expense	4.0M	4.0M	6.5M	10.7M	2.5M
Bottom Line
Net Income	21.3M	18.9M	40.0M	60.3M	70.9M
Earnings from Cont. Ops	21.3M	18.9M	40.0M	60.3M	70.9M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	21.3M	18.9M	40.0M	60.3M	70.9M
Per Share
Basic EPS	CN¥0.31	CN¥0.28	CN¥0.59	CN¥0.89	CN¥1.19
Diluted EPS	CN¥0.31	CN¥0.28	CN¥0.59	CN¥0.89	CN¥1.19
Revenue Per Share	CN¥6.69	CN¥6.74	CN¥7.02	CN¥7.85	CN¥9.20
Shares
Basic Shares Outstanding	68.0M	68.0M	68.0M	68.0M	59.5M
Diluted Shares Outstanding	68.0M	68.0M	68.0M	68.0M	59.5M
Profitability Metrics
EBITDA	—	61.8M	85.1M	98.8M	84.6M
D&A	—	38.3M	38.2M	30.3M	22.5M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026